Research progress of dyslipidemia in the pathogenesis of primary open angle glaucoma

doi:10.3877/cma.j.issn.2095-2007.2023.01.007

Abstract

Abstract:

Primary open angle glaucoma (POAG) is the most common type of glaucoma. Recently, the role of dyslipidemia in the incidence of POAG has caused wide attention, which may influence the occurrence of POAG by intraocular pressure, blood circulation, retinal ganglion cells, lipid-soluble vitamin levels and gut microbiota. The research progress and possible mechanism of dyslipidemia and POAG were reviewed in this paper.

Key words: Dyslipidemia, Primary open angle glaucoma, Intraocular pressure, Lipid-soluble vitamin, Gut microbiota

Ruyue Li, Ruiqi Pang, Ningli Wang. Research progress of dyslipidemia in the pathogenesis of primary open angle glaucoma[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(01): 35-39.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2023.01.007

https://zhykyxzz.cma-cmc.com.cn/EN/Y2023/V13/I01/35

Figures/Tables 1

References 56

[1]	中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志，2020，35(9)：833－854.
[2]	Wang S, Xu L, Jonas JB, et al. Dyslipidemia and eye diseases in the adult Chinese population: the Beijing eye study[J]. PLoS One, 2012, 7(3): e26871.
[3]	Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride－rich lipoproteins and high－density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management[J]. Eur Heart J, 2011, 32(11): 1345－1361.
[4]	Wang S, Bao X. Hyperlipidemia, blood lipid level, and the risk of glaucoma: a meta－analysis[J]. Invest Ophthalmol Vis Sci, 2019, 60(4): 1028－1043.
[5]	Kim YH, Jung SW, Nam GE, et al. High intraocular pressure is associated with cardiometabolic risk factors in South Korean men: Korean National Health and Nutrition Examination Survey, 2008—2010[J]. Eye (Lond), 2014, 28(6): 672－679.
[6]	中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华全科医师杂志，2017，16(1): 15－35.
[7]	Marcus MW, Müskens RP, Ramdas WD, et al. Cholesterol－lowering drugs and incident open－angle glaucoma: a population－based cohort study[J]. PLoS One, 2012, 7(1): e29724.
[8]	Pertl L, Mossböck G, Wedrich A, et al. Triglycerides and open angle glaucoma－a meta－analysis with meta－regression[J]. Sci Rep, 2017, 7(1): E7829.
[9]	Kim HA, Han K, Lee YA, et al. Differential association of metabolic risk factors with open angle glaucoma according to obesity in a korean population[J]. Sci Rep, 2016, 6: 38283.
[10]	Zhang Y, Zhang Q, Thomas R, et al. Association of hyper－triglyceridemia and incident glaucoma in a rural Chinese population: The Handan Eye Study[J]. Transl Vis Sci Technol, 2021, 10(8): 25.
[11]	Lee SH, Kim GA, Lee W, et al. Vascular and metabolic comorbidities in open－angle glaucoma with low and high－teen intraocular pressure: a cross－sectional study from South Korea[J]. Acta Ophthalmol, 2017, 95(7): e564－e574.
[12]	PavljaseviĉS, Asĉeriĉ M. Primary open－angle glaucoma and serum lipids[J]. Bosn J Basic Med Sci, 2009, 9(1): 85－88.
[13]	Ko F, Boland MV, Gupta P, et al. Diabetes, triglyceride levels, and other risk factors for glaucoma in the national health and nutrition examination survey 2005—2008[J]. Invest Ophthalmol Vis Sci, 2016, 1；57(4): 2152－2157.
[14]	Talwar N, Musch DC, Stein JD. Association of daily dosage and type of statin agent with risk of open－angle glaucoma[J]. JAMA Ophthalmol, 2017, 135(3): 263－267.
[15]	Kim MJ, Kim MJ, Kim HS, et al. Risk factors for open－angle glaucoma with normal baseline intraocular pressure in a young population: the Korea National Health and Nutrition Examination Survey[J]. Clin Exp Ophthalmol, 2014, 42(9): 825－832.
[16]	Lin HC, Chien CW, Hu CC, et al. Comparison of comorbid conditions between open－angle glaucoma patients and a control cohort: a case－control study[J]. Ophthalmology, 2010, 117(11): 2088－2095.
[17]	Newman－Casey PA, Talwar N, Nan B, et al. The relationship between components of metabolic syndrome and open－angle glaucoma[J]. Ophthalmology, 2011, 118(7): 1318－1326.
[18]	Xu M, Li S, Zhu J, et al. Plasma lipid levels and risk of primary open angle glaucoma: a genetic study using Mendelian randomization[J]. BMC Ophthalmol, 2020, 20(1): 390.
[19]	dos－Santos MG, Makk S, Berghold A, et al. Intraocular pressure difference in Goldmann applanation tonometry versus Perkins hand－held applanation tonometry in overweight patients[J]. Ophthalmology, 1998, 105(12): 2260－2263.
[20]	Kim M, Jeoung JW, Park KH, et al. Metabolic syndrome as a risk factor in normal－tension glaucoma[J]. Acta Ophthalmol, 2014, 92(8): e637－e643.
[21]	韩菲，殷玲，路国涛，等. 高密度脂蛋白与代谢综合征的关系[J]. 医学综述，2020，26(2)：356－360，365.
[22]	Hwang IC, Lee YJ, Bae JH. A meta－analysis of glaucoma risk in hyperlipidemic individuals: a critical problem in design[J]. Invest Ophthalmol Vis Sci, 2016, 57(14): 6339－6340.
[23]	McCann P, Hogg RE, Fallis R, et al. The effect of statins on intraocular pressure and on the incidence and progression of glaucoma: a systematic review and meta－analysis[J]. Invest Ophthalmol Vis Sci, 2016, 57(6): 2729－2748.
[24]	Kim MJ, Park KH, Kim CY, et al. The distribution of intraocular pressure and associated systemic factors in a Korean population: the Korea National Health and Nutrition Examination Survey[J]. Acta Ophthalmol, 2014, 92(7): e507－e513.
[25]	Zheng Y ，Cheung CY, Wong TY, et al. Influence of height, weight, and body mass index on optic disc parameters[J]. Invest Ophthalmol Vis Sci, 2010, 51(6): 2998－3002.
[26]	Xu L, Wang YX, Wang S, et al. Neuroretinal rim area and body mass index[J]. PLoS One, 2012, 7(1): e30104.
[27]	McGwin G, McNeal S, Owsley C, et al. Statins and other cholesterol－lowering medications and the presence of glaucoma[J]. Arch Ophthalmol, 2004, 122(6): 822－826.
[28]	Stein JD, Newman－Casey PA, Talwar N, et al. The relationship between statin use and open－angle glaucoma[J]. Ophthalmology, 2012, 119(10): 2074－2081.
[29]	Khawaja AP, Chan MP, Broadway DC, et al. Systemic medication and intraocular pressure in a British population: the EPIC－Norfolk Eye Study[J]. Ophthalmology, 2014, 121(8): 1501－1507.
[30]	Chen HY, Hsu SY, Chang YC, et al. Association between statin use and open－angle glaucoma in hyperlipidemia patients: A Taiwanese Population－based Case－control Study[J]. Medicine (Baltimore), 2015, 94(45): e2018.
[31]	Song J, Deng PF, Stinnett SS, et al. Effects of cholesterol－lowering statins on the aqueous humor outflow pathway[J]. Invest Ophthalmol Vis Sci, 2005, 46(7): 2424－2432.
[32]	Jia LY, Gong B, Pang CP, et al. Correction of the disease phenotype of myocilin－causing glaucoma by a natural osmolyte[J]. Invest Ophthalmol Vis Sci, 2009, 50(8): 3743－3749.
[33]	乐世俊，王文晓，陶慧娟，等. 肠道菌群－TMA－TMAO代谢途径与心血管疾病的研究进展[J]. 中华心血管病杂志，2020，48(2)：159－163.
[34]	Skrzypecki J, Izdebska J, Kamińska A, et al. Glaucoma patients have an increased level of trimethylamine, a toxic product of gut bacteria, in the aqueous humor: a pilot study[J]. Int Ophthalmol, 2021, 41(1): 341－347.
[35]	Yoo W, Zieba JK, Foegeding NJ, et al. High－fat diet－induced colonocyte dysfunction escalates microbiota－derived trimethylamine N－oxide[J]. Science, 2021, 373(6556): 813－818.
[36]	Bulpitt CJ, Hodes C, Everitt MG. Intraocular pressure and systemic blood pressure in the elderly[J]. Br J Ophthalmol, 1975, 59(12): 717－720.
[37]	Shiose Y. The aging effect on intraocular pressure in an apparently normal population[J]. Arch Ophthalmol, 1984, 102(6): 883－887.
[38]	Fu J, Bonder MJ, Cenit MC, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids[J]. Circ Res, 2015, 117(9): 817－24.
[39]	Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome[J]. J Hypertens, 2007, 25(5): 909－920.
[40]	MacDougald OA, Burant CF. Obesity and metabolic perturbations after loss of aquaporin 7, the adipose glycerol transporter[J]. Proc Natl Acad Sci USA, 2005, 102(31): 10759－10760.
[41]	常田，杨雪丽，王鹏旭，等. 肠道菌群与糖尿病眼部并发症关系的研究进展[J]. 中华糖尿病杂志，2020，12(7)：551－554.
[42]	Andriessen EM, Wilson AM, Mawambo G, et al. Gut microbiota influences pathological angiogenesis in obesity－driven choroidal neovascularization[J]. EMBO Mol Med, 2016, 8(12): 1366－1379.
[43]	Deschênes MC, Descovich D, Moreau M, et al. Postmenopausal hormone therapy increases retinal blood flow and protects the retinal nerve fiber layer[J]. Invest Ophthalmol Vis Sci, 2010, 51(5): 2587－2600.
[44]	Rowan S, Taylor A. Gut microbiota modify risk for dietary glycemia－induced age－related macular degeneration[J]. Gut Microbes, 2018, 9(5): 452－457.
[45]	Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive－leptin concentrations in normal－weight and obese humans[J]. N Engl J Med. 1996, 334(5): 292－295.
[46]	López－Riquelme N, Villalba C, Tormo C, et al. Endothelin－1 levels and biomarkers of oxidative stress in glaucoma patients[J]. Int Ophthalmol, 2015, 35(4): 527－532.
[47]	Wang SY, Singh K, Lin SC. Glaucoma and vitamins A, C, and E supplement intake and serum levels in a population－based sample of the United States[J]. Eye (Lond), 2013, 27(4): 487－494.
[48]	Zhang F, Wang S, Signore AP, et al. Neuroprotective effects of leptin against ischemic injury induced by oxygen－glucose deprivation and transient cerebral ischemia[J]. Stroke, 2007, 38(8): 2329－2336.
[49]	Saccà SC, Gandolfi S, Bagnis A, et al. The Outflow Pathway: A Tissue With Morphological and Functional Unity[J]. J Cell Physiol, 2016, 231(9): 1876－93.
[50]	田佳鑫，曹凯，石砚，等. 原发性开角型青光眼全身危险因素及眼体同治的系统回顾和Meta分析[J]. 中华眼科医学杂志(电子版)，2019，9(5)：281－291.
[51]	Kim HJ, Min KB, Min JY. Neuropeptide Y gene－by－psychosocial stress interaction effect is associated with obesity in a Korean population[J]. Psychoneuroendocrinology, 2016, 69: 10－15.
[52]	Santos－Carvalho A, Elvas F, Alvaro AR, et al. Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate[J]. Cell Death Dis, 2013, 4(5): e636.
[53]	Kishida K, Naka KI. Amino acids and the spikes from the retinal ganglion cells[J]. Science, 1967, 156(3775): 648－650.
[54]	Cao X, Guo Y, Wang Y, et al. Effects of high－fat diet and Apoe deficiency on retinal structure and function in mice[J]. Sci Rep, 2020, 10(1): 18601.
[55]	Ramdas WD, Schouten JSAG, Webers CAB. The effect of vitamins on glaucoma: a systematic review and meta－analysis[J]. Nutrients, 2018, 10(3): 359.
[56]	Pang R, Feng S, Cao K, et al. Association of serum retinol concentration with normal－tension glaucoma[J]. Eye (Lond), 2022, 36(9): 1820－1825.

第一作者	发表年份	降脂药物类型	青光眼类型	主要结果
McGwin等^[27]	2004	他汀类降脂药物－非他汀类降脂药物	POAG	因任何原因长期口服他汀类药物者患POAG的风险降低，服药时间超过23个月者效果尤其明显。非他汀类降胆固醇药物降低POAG风险仅限于使用时间少于12个月的患者。他汀类和非他汀类药物联合使用时，POAG发生风险最低
Marcus等^[7]	2012	他汀类降脂药物	POAG	他汀类药物的使用可能对不依赖眼压升高型青光眼的发展具有保护作用
Stein等^[28]	2012	他汀类降脂药物－非他汀类降脂药物	POAG	服用他汀类药物治疗高脂血症的患者发生POAG、从可疑青光眼进展为POAG以及需要青光眼治疗相关药物的风险降低，而进展期POAG患者并未减少手术需求。服用他汀类药物的时间越长，保护作用越大。
Khawaja等^[29]	2014	他汀类降脂药物	眼压	调整混杂因素后，他汀类药物的使用与较低的眼压显著相关。药物类型、使用时间、既往用药史等均与POAG的发生与发展无显著相关。
Chen等^[30]	2015	他汀类降脂药物	POAG	使用较高剂量他汀类药物(>120 DDD/年)会增加POAG风险
McCann等^[23]	2016	他汀类降脂药物	青光眼	短期使用他汀类药物(<2年)使青光眼发病率降低了4%
Talwar等^[14]	2017	他汀类降脂药物	POAG	POAG发生风险降低的程度与每日摄入的他汀类药物剂量无关。在调整了基线LDL－C水平和其他混杂因素后，每增加1个月他汀类药物的使用，POAG发病风险降低1%；连续用药2年者发病风险降低21%

第一作者	发表年份	降脂药物类型	青光眼类型	主要结果
McGwin等^[27]	2004	他汀类降脂药物－非他汀类降脂药物	POAG	因任何原因长期口服他汀类药物者患POAG的风险降低，服药时间超过23个月者效果尤其明显。非他汀类降胆固醇药物降低POAG风险仅限于使用时间少于12个月的患者。他汀类和非他汀类药物联合使用时，POAG发生风险最低
Marcus等^[7]	2012	他汀类降脂药物	POAG	他汀类药物的使用可能对不依赖眼压升高型青光眼的发展具有保护作用
Stein等^[28]	2012	他汀类降脂药物－非他汀类降脂药物	POAG	服用他汀类药物治疗高脂血症的患者发生POAG、从可疑青光眼进展为POAG以及需要青光眼治疗相关药物的风险降低，而进展期POAG患者并未减少手术需求。服用他汀类药物的时间越长，保护作用越大。
Khawaja等^[29]	2014	他汀类降脂药物	眼压	调整混杂因素后，他汀类药物的使用与较低的眼压显著相关。药物类型、使用时间、既往用药史等均与POAG的发生与发展无显著相关。
Chen等^[30]	2015	他汀类降脂药物	POAG	使用较高剂量他汀类药物(>120 DDD/年)会增加POAG风险
McCann等^[23]	2016	他汀类降脂药物	青光眼	短期使用他汀类药物(<2年)使青光眼发病率降低了4%
Talwar等^[14]	2017	他汀类降脂药物	POAG	POAG发生风险降低的程度与每日摄入的他汀类药物剂量无关。在调整了基线LDL－C水平和其他混杂因素后，每增加1个月他汀类药物的使用，POAG发病风险降低1%；连续用药2年者发病风险降低21%

Please choose a citation manager

Content to export